The "spin off" of Fosun Pharmaceutical is going further, and gland Pharma plans to be listed in India

On November 2, Fosun Pharmaceutical announced that its subsidiary "gland" Pharma "is going to be listed in India, which has aroused heated discussion among the shareholders This is the second time that Fosun is listed in Hong Kong after Fosun is split and Hong Hanlin is listed in Hong Kong Some netizens worry that overseas listing will affect the goodwill of Fosun, but others think that as long as it can be realized in time, goodwill is not a problem (photo source: Fosun Pharmaceutical announcement) according to the announcement, glandpharma was founded in 1978, headquartered in Hyderabad, India It is mainly engaged in the development and production of small molecule injection generic drugs Its chairman is lauyiukwan Stanley, and its chief executive officer is srinivassadu Glandpharma is the first injection drug manufacturer approved by FDA in India, and has obtained GMP certification in major regulatory markets around the world Its business income mainly comes from the United States and Europe As of the date of this announcement, the company (through its holding subsidiaries) holds 74% of the equity of gladpharma As of December 31, 2018, glandpharma's total assets are about 624.502 million yuan, owner's equity is about 4796.26 million yuan, and total liabilities are about 1448.76 million yuan; in 2018, glandpharma's operating revenue is about 1912.92 million yuan, and its net profit is about 283.25 million yuan The above data are consolidated basis, including amortization of appraisal value-added Two years ago, Fosun Pharmaceutical purchased gland Pharma for us $1.091 billion (equivalent to RMB 7.258 billion), and now the operation mode of listing again is amazing Netizens therefore expressed their opinions: @ shareholder 1: in 2018, gland Pharma's revenue and net profit increased by about 19.50% and 29.02% respectively compared with the same period in 2017 In the first half of this year, gland Pharma achieved a year-on-year growth of 18% in operating revenue, 29% in net profit, and maintained a compound annual growth rate of about 30% In 2019, Q3 was approved by FDA, and the largest Chinese enterprise of Anda is Fosun Pharmaceutical, reaching 8 (4 times of the second place), among which 7 are from gland, the Indian subsidiary of Fosun Pharmaceutical, which are respectively Gelong ammonium bromide injection, docosterol sustained-release tablets, tanrolesmo injection, esmolol hydrochloride injection, zoledronic acid injection, orotadine hydrochloride eye drops and tablets A duloxetine hydrochloride sustained release capsule from Chongqing Yaoyou, a subsidiary company, has always implemented the idea of layout the whole global industrial chain Now the behavior of its subsidiary listed in India is even more evidence of this In some ways, Fosun is a real international company, and the pattern is naturally different @Shareholder 2: gland Pharma has a compound annual growth rate of about 30%, and its net profit is expected to be RMB 550 million this year At present, India's domestic economic development is very similar to that of China 20 years ago High quality pharmaceutical companies like gland Pharma can be regarded as Hengrui 10 years ago Under the guidance of Fosun medicine, there is a promising future If Fosun didn't lay out gland Pharma in advance two years ago, I'm afraid that it will spend 1.5 billion US dollars this year and won't be able to acquire 74% of the controlling right of gland pharma Fosun's goodwill will only increase in value and not decrease in value @ shareholder 3: all the behaviors of Fosun in recent years seem to have the shadow of Johnson & Johnson at the beginning Taking Johnson & Johnson as the benchmark, it fully shows Fosun's strong strategic vision and layout @Shareholder 4: personal opinion: after the listing of Fuhong Hanlin, the share price did not rise, but the lesson of the fall disappointed the executives of Fuxing They realized that only when the share price suddenly improved could the limit board rise! This sudden release is good Fosun stock is bound to rise! I pinched my fingers and calculated that the opening on Monday should be at least 10 cents higher! (photo source: Dongfang fortune Com) as of 11:30 a.m on Monday, November 4, Fosun's stock volatility was also expected and gratifying The author also hopes that no matter what operation mode, more powerful Chinese pharmaceutical companies will be used to try to go abroad and show the powerful power of Chinese pharmaceutical companies to the foreign market Source: Dongfang fortune.com, pharmaceutical intelligence news and other penicillin statements: this point of view only represents the author and does not represent the position of pharmaceutical intelligence.com Welcome to exchange and supplement in the message area If you need to reprint, please be sure to indicate the author and source of the article.